Protalix Biotherapeutics Inc Share Price TEL AVIV STOCK EXCHANGE
Stocks
US74365A1016
Pharmaceuticals
| Market Cap | 19Cr 5.86TCr 17Cr 16Cr 14Cr 27Cr 1.85TCr 27Cr 185.44Cr 73Cr 904.61Cr 72Cr 70Cr 3.12TCr | P/E 2026 * |
12.4x | P/E 2027 * | 48.2x |
|---|---|---|---|---|---|
| Enterprise Value | 19Cr 5.86TCr 17Cr 16Cr 14Cr 27Cr 1.85TCr 27Cr 185.44Cr 73Cr 904.61Cr 72Cr 70Cr 3.12TCr | EV / Sales 2026 * |
2.45x | EV / Sales 2027 * | 2.84x |
| Free-Float |
96.12% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Protalix Biotherapeutics Inc
| 1 day | -1.13% |
| Manager | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 59 | 30/06/2019 |
Gilad Mamlok
DFI | Director of Finance/CFO | 57 | 24/08/2025 |
Ori Kalid
CTO | Chief Tech/Sci/R&D Officer | - | 01/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amos Bar Shalev
BRD | Director/Board Member | 73 | 01/07/2008 |
Aharon Schwartz
BRD | Director/Board Member | 82 | 01/11/2014 |
Dror Bashan
BRD | Director/Board Member | 59 | 30/06/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.13% | -11.89% | - | - | 19Cr | |
| -2.73% | -3.51% | +48.62% | +152.87% | 1,05100Cr | |
| -1.67% | -3.18% | +52.00% | +56.75% | 61TCr | |
| -0.44% | +2.14% | +33.88% | +84.04% | 45TCr | |
| -0.75% | -1.46% | +28.32% | +22.33% | 33TCr | |
| -1.52% | -0.95% | +33.38% | +38.39% | 28TCr | |
| -1.70% | -3.54% | +20.26% | +17.88% | 26TCr | |
| -0.58% | +1.78% | -20.89% | -38.37% | 22TCr | |
| -0.58% | +0.21% | +23.55% | +56.94% | 20TCr | |
| -0.80% | +2.60% | +23.09% | +68.71% | 17TCr | |
| Average | -1.19% | +0.54% | +26.91% | +51.06% | 39.72TCr | |
| Weighted average by Cap. | -1.56% | +0.02% | +35.25% | +75.58% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.83Cr 2.39TCr 6.86Cr 6.34Cr 5.83Cr 11Cr 755.07Cr 11Cr 76Cr 30Cr 369.36Cr 29Cr 29Cr 1.27TCr | 6.76Cr 2.06TCr 5.92Cr 5.47Cr 5.03Cr 9.51Cr 651.55Cr 9.66Cr 65Cr 26Cr 318.72Cr 25Cr 25Cr 1.1TCr |
| Net income | 1.57Cr 480.34Cr 1.38Cr 1.27Cr 1.17Cr 2.21Cr 151.62Cr 2.25Cr 15Cr 5.96Cr 74Cr 5.9Cr 5.77Cr 255.46Cr | 40.74L 124.45Cr 35.7L 32.98L 30.35L 57.35L 39Cr 58.25L 3.94Cr 1.54Cr 19Cr 1.53Cr 1.5Cr 66Cr |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
